Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Figures corrected NBB
Corrected annual account filed for 2024.
Financials
Financial year 2025
NEUVASQ BIOTECHNOLOGIES from Charleroi, company number BE0762966663, closed financial year 2025 with a result of € -2.6 million after tax. For that financial year NEUVASQ BIOTECHNOLOGIES recorded a gross margin of € 641,586 and equity of € 6.3 million. Compared with financial year 2024, the result moved from € -2.5 million to € -2.6 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 6.3 million
▲ 61% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.6 million
▼ 3 % more loss than in 2024
Profit after tax over the fiscal year.
€ 6 million
▲ 97% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -8.7 million.
People and assets in 2025
9.3
▲ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 879,592
▲ 6% vs 2024
€ 94,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 5
▼ 99% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 323,311
▲ 42% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 144,743
▼ 13% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -218,533 | € 475,433 | € 556,541 | € 641,586 | ▲ 15% |
| Profit after taxes | € -1,111,908 | € -2,002,399 | € -2,519,895 | € -2,599,256 | ▼ € 79,362 |
| Equity | € 3,430,316 | € 1,427,917 | € 3,908,021 | € 6,308,765 | ▲ 61% |
| Total debts | € 279,842 | € 1,808,459 | € 395,230 | € 917,511 | ▲ 132% |
| Cash | € 3,139,005 | € 1,307,226 | € 3,026,521 | € 5,956,677 | ▲ 97% |
| Retained profit | € -1,575,684 | € -3,578,083 | € -6,097,979 | € -8,697,235 | ▼ € 2.6 million |
| Balance sheet total | € 3,710,158 | € 3,236,376 | € 4,303,251 | € 7,226,276 | ▲ 68% |
| Employees (FTE) | 2.9 | 7.1 | 8.2 | 9.3 | ▲ 1.1 |
Key figures of NEUVASQ BIOTECHNOLOGIES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NEUVASQ BIOTECHNOLOGIES?
What happened at NEUVASQ BIOTECHNOLOGIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- GEMA SRL stepped down as director. NBB
- Yves Ribeill stepped down as director. NBB
- NEWTON BIOCAPITAL PARTNER SRL stepped down as director. NBB
- Benoit Vanhollebeke stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- 50°NORTH VENTURES stepped down as director. NBB
- SFPI SA stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.6 million. Source: NBB ↗
In short
From € 1.1 million loss in 2022 to € 2.6 million loss in 2025.
On average € 69,000 of value added per employee in 2025.
A new publication or filing at NEUVASQ BIOTECHNOLOGIES? We notify you, reason included.
Follow NEUVASQ BIOTECHNOLOGIESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Newton Biocapital I, pricaf privée de droit belge, FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ, THEODORUS IV, Wallonie Entreprendre, INVESTSUD TECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
NEUVASQ BIOTECHNOLOGIESThe shares are held by Newton Biocapital I, pricaf privée de droit belge (25.5%), FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ (17.9%), THEODORUS IV (16.8%), Wallonie Entreprendre (14.3%) and INVESTSUD TECH (0.8%).
Directors
According to the 2025 annual accounts
Chairman of the board · represented by Michel Allé
Also active at: D'Ieteren Group, EURVEST, EPICS THERAPEUTICS, LINEAS GROUP, LINEAS
since 2022 · until 2028
Director · represented by Pierre Detrixhe
Also active at: SYNERGIA MEDICAL, Newton Biocapital I, pricaf privée de droit belge, Newton Biocapital I Investment Pool, EPICS THERAPEUTICS, DeuterOncology, Aboleris Holdco, FLANDERSBIO
since 2025 · until 2027
Benoit Vanhollebeke
Director
since 2021 · until 2027
Director · represented by Christina Franssen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +223 more
since 2021 · until 2027
Director · represented by Denis Bedoret
Also active at: EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev, THEODORUS III, THEODIRIS, ALLERINVEST, KABANDY, SEEDER FUND +13 more
since 2021 · until 2027
Director · represented by Francois Fontaine
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale, COMETSAMBRE, ASCO INDUSTRIES, ZEPHYR - FIN, Sabena Aerospace Engineering, reMYND +57 more
since 2025 · until 2027
Yves Ribeill
Director
since 2022 · until 2028
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Auguste Piccard 48
6041 Charleroi
Rue Adrienne Bolland 8
6041 Charleroi
Active since 1 January 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →SYNABS
€ 742,551 gross margin · 2025
European Infrared Technologies
€ 53,354 gross margin · 2024
HEARTKINETICS
€ -463,720 gross margin · 2022
Genflow Biosciences
€ -264,246 gross margin · 2025
CANCER STATE THERAPEUTICS
€ -105,252 gross margin · 2025
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0762.966.663
- VAT number
- BE 0762.966.663
- Registered office
- Rue Auguste Piccard 48, 6041 Charleroi
- Names & denominations
- NEUVASQ BIOTECHNOLOGIES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 February 2021
- Peppol
- Active · Active since 15 Mar 2021
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten op het gebied van voeding
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van medische beeldvorming en medische laboratoria
Overige zakelijke dienstverlening, neg
+3